Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. (Q34529131)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27249175 AND SRC:MED&resulttype=core&format=json

3 April 2020

review article

1 reference

title

Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27249175 AND SRC:MED&resulttype=core&format=json

3 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27249175 AND SRC:MED&resulttype=core&format=json

3 April 2020

Boon Cher Goh

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27249175 AND SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Wei-Peng Yong

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27249175 AND SRC:MED&resulttype=core&format=json

3 April 2020

Soo-Chin Lee

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27249175 AND SRC:MED&resulttype=core&format=json

3 April 2020

language of work or name

English

0 references

publication date

13 June 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27249175 AND SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

3 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27249175 AND SRC:MED&resulttype=core&format=json

3 April 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27249175 AND SRC:MED&resulttype=core&format=json

3 April 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27249175 AND SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

911-922

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27249175 AND SRC:MED&resulttype=core&format=json

RET, ROS1 and ALK fusions in lung cancer

3 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Is the $1,000 genome for real?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

International network of cancer genome projects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

The Cancer Genome Atlas Pan-Cancer analysis project

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Quantitative monitoring of gene expression patterns with a complementary DNA microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Biomarker Tests for Molecularly Targeted Therapies: Laying the Foundation and Fulfilling the Dream

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Tumour heterogeneity in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Genomics-driven oncology: framework for an emerging paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Ceritinib in ALK-rearranged non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

The BATTLE trial: personalizing therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Genetic factors affecting drug disposition in Asian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Prioritizing targets for precision cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Long-term impact of the 70-gene signature on breast cancer outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Multigene prognostic tests in breast cancer: past, present, future

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Cancer of unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Cancer of unknown primary site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

A second-generation microRNA-based assay for diagnosing tumor tissue origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Molecular diagnosis of nasopharyngeal carcinoma using detection of Epstein-Barr virus latent membrane protein-1 gene in cervical metastatic lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

The role of human papilloma virus and p16 in occult primary of the head and neck: a comprehensive review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

The life history of 21 breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Robust enumeration of cell subsets from tissue expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

The prognostic landscape of genes and infiltrating immune cells across human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Pan-cancer patterns of somatic copy number alteration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Comprehensive molecular characterization of gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Signatures of mutational processes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

An integrated encyclopedia of DNA elements in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Emerging patterns of somatic mutations in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Role of non-coding sequence variants in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Highly recurrent TERT promoter mutations in human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

TERT promoter mutations in familial and sporadic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Non-coding recurrent mutations in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Whole-genome characterization of chemoresistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Whole genomes redefine the mutational landscape of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Exosome-Mediated Metastasis: From Epithelial-Mesenchymal Transition to Escape from Immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Glypican-1 identifies cancer exosomes and detects early pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Analysis of circulating tumor DNA to monitor metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Genome sequencing identifies a basis for everolimus sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Precision medicine for metastatic breast cancer--limitations and solutions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Feasibility of low-throughput next generation sequencing for germline DNA screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/17425255.2016.1196187

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NATURE11156

Identifiers

DOI

10.1080/17425255.2016.1196187

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27249175 AND SRC:MED&resulttype=core&format=json

release_5fodtis2kfewhczhncmeze6zj4

3 April 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5fodtis2kfewhczhncmeze6zj4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference